Company Overview of S-TARget therapeutics GmbH
S-TARget therapeutics GmbH, a biotech company, develops therapeutic vaccines to cure and prevent allergic diseases. Its SG100, an active immunotherapy prototype that is used to cure and prevent allergic asthma induced by house dust mite (HDM). The company’s SG100 vaccine comprises of active ingredients that work together in a two-module system, such as a generic module (warhead) and a disease-specific module (immunogen). S-TARget therapeutics GmbH was founded in 2010 and is based in Vienna, Austria.
Founded in 2010
43 664 5160032
Key Executives for S-TARget therapeutics GmbH
Similar Private Companies By Industry
|AOP Orphan Pharmaceuticals AG||Europe|
|AVIR Green Hills Biotechnology AG||Europe|
|Bartenstein Holding GmbH||Europe|
|BioLife Science Forschungs- und Entwicklungsges. m. b. H.||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Bloomberg L.P.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact S-TARget therapeutics GmbH, please visit www.s-target.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.